Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468136) titled 'Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas' on March 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mayo Clinic
Condition:
Anaplastic Oligodendroglioma
Astrocytoma, IDH-Mutant, Grade 3
Astrocytoma, IDH-Mutant, Grade 4
Diffuse Astrocytoma
Glioblastoma, IDH-Wildtype
Malignant Glioma
Intervention:
Procedure: Biospecimen Collection
Drug: Eflornithine
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Biol...